Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom
Endoscopy · 01.06.2025 · 57 (06) · 583-592
DOI: 10.1055/a-2495-2813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.06.2025. Verfasst von Dawn M Cooper und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cook Medical (UK), Altrincham, United Kingdom of Great Britain and Northern Ireland. Hauptthemen laut MEDLINE: Gastrointestinal Hemorrhage, Hemostatics, Hemostasis, Endoscopic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Randomized controlled trials have shown that hemostatic powder (TC-325) results in greater immediate hemostasis and lower 30-day rebleeding rates than standard endoscopic therapy (SET) for management of malignant upper gastrointestinal bleeding (MUGIB). We explored whether TC-325 would be a cost-effective first-line option for patients with MUGIB compared with SET in the United Kingdom. A decision tree was developed for patients with MUGIB, assessing initial therapy with TC-325 or SET over a 30-day period. Patients with failed initial hemostasis or a rebleed within 30 days underwent further endoscopic treatment, escalation to either transcatheter arterial embolization or surgery, or radiotherapy. Overall 30-day mortality was applied. Costs, in GBP, were based on the United Kingdom National Health Services costs for 2023/2024. Results were reported as incremental differences in cost, quality-adjusted life years (QALY), and net monetary benefit. Deterministic and probabilistic sensitivity analyses and scenario analyses were performed. The cost of treating MUGIB patients with TC-325 was £245.88 lower than treatment with SET, with an incremental increase of 0.001 QALYs. TC-325 remained a cost-saving approach in sensitivity and scenario analyses. Probabilistic sensitivity analysis revealed that TC-325 was more effective and cost saving in 80.1% of simulations (range 67.5%–98.63%). Initial treatment of MUGIB with TC-325 compared with SET was more effective (higher primary hemostasis and lower 30-day rebleeding) and cost saving owing to the requirement for fewer interventions, readmissions, and length of stay. Additional studies are needed to address model uncertainties in the follow-up management of these complex patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cook Medical (UK), Altrincham, United Kingdom of Great Britain and Northern Ireland.
- Digestive Disease and Surgery Institute, Cleveland Clinic London, London, United Kingdom of Great Britain and Northern Ireland.
- Department of Gastroenterology, Royal Glamorgan Hospital, Llantrisant, United Kingdom of Great Britain and Northern Ireland.
- Department of Gastroenterology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom of Great Britain and Northern Ireland.
- Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom of Great Britain and Northern Ireland.
- Division of Gastroenterology, Department of Medicine, McGill University, Montreal, Canada.
ORCID-Profile: Dawn M Cooper
Zitieren
APA
Cooper, D. M., Norton, B., Hawkes, N. D., Hebbar, S., Telese, A., Morris, J., Haidry, R., & Barkun, A. (2025). Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom. Endoscopy, 57(06), 583-592. https://doi.org/10.1055/a-2495-2813
Vancouver
Cooper DM, Norton B, Hawkes ND, Hebbar S, Telese A, Morris J, et al. Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom. Endoscopy. 2025;57(06):583-592. doi:10.1055/a-2495-2813
BibTeX
@article{Cooper2025,
author = {Cooper, Dawn M and Norton, Benjamin and Hawkes, Neil D and Hebbar, Srisha and Telese, Andrea and Morris, John and Haidry, Rehan and Barkun, Alan},
title = {Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom},
journal = {Endoscopy},
year = {2025},
volume = {57},
number = {06},
pages = {583--592},
doi = {10.1055/a-2495-2813}
}
EUVIMED